Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.23
+0.01 (0.19%)
At close: Nov 20, 2024, 4:00 PM
5.31
+0.08 (1.53%)
Pre-market: Nov 21, 2024, 4:04 AM EST
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $416.00K in the quarter ending September 30, 2024, a decrease of -99.59%. This brings the company's revenue in the last twelve months to $196.49M, down -33.22% year-over-year. In the year 2023, Amylyx Pharmaceuticals had annual revenue of $380.79M with 1,612.94% growth.
Revenue (ttm)
$196.49M
Revenue Growth
-33.22%
P/S Ratio
1.81
Revenue / Employee
$511,680
Employees
384
Market Cap
356.07M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
Dec 31, 2019 | 1.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ZimVie | 451.29M |
Tactile Systems Technology | 285.05M |
AirSculpt Technologies | 188.78M |
Valneva SE | 176.82M |
Akebia Therapeutics | 169.88M |
ProQR Therapeutics | 20.51M |
4D Molecular Therapeutics | 17.00K |
Q32 Bio | -14.66M |
AMLX News
- 2 days ago - Best Cheap Stocks To Buy Now (Under $10) - Kiplinger
- 11 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - Business Wire
- 16 days ago - Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - Business Wire
- 4 weeks ago - Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - Business Wire
- 5 weeks ago - Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - Business Wire
- 6 weeks ago - Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - PRNewsWire
- 3 months ago - Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire